Comparative Pharmacology
Head-to-head clinical analysis: HIPREX versus UREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPREX versus UREX.
HIPREX vs UREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hippuric acid, the active metabolite of methenamine, acidifies urine and releases formaldehyde, which denatures bacterial proteins and nucleic acids, bactericidal activity requires acidic urine (pH < 5.5).
Urex (methenamine hippurate) is hydrolyzed in acidic urine to formaldehyde and ammonia. Formaldehyde denatures bacterial proteins and nucleic acids, exerting a nonspecific bactericidal effect. The hippuric acid component maintains urinary acidity.
1 gram orally twice daily (every 12 hours) with meals
100 mg orally twice daily for 3 days (uncomplicated UTI) or 100 mg orally once daily for 5 days (prophylaxis).
None Documented
None Documented
3-6 hours (methenamine); clinical context: prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 14-18 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 40 hours in severe impairment), necessitating dose adjustment.
Renal excretion: >90% as unchanged drug (methenamine) and formaldehyde; biliary/fecal: <5%.
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination accounts for <5%.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective